The Pancreatic Cancer Early Detection (PRECEDE) Consortium: A Research Platform to Study Risk, Genetics, and Early Detection of Pancreatic Cancer with Jessica Everett, MS, CGC

• Pancreatic cancer has a dismal 5-year survival rate of 11%. It is projected to become the second leading cause of cancer-related death in the United States by 2030, largely because 85% of patients are diagnosed with late stage disease. Recent analysis of 2012 SEER data found that 5-year survival for stage 1a pancreatic cancer reached 83%, highlighting the potential for early detection to dramatically change the trajectory of this disease. At least 10% of patients with pancreatic cancer carry a pathogenic variant in a known cancer risk gene, and another 10-15% have a first degree relative with pancreatic cancer without an identifiable genetic cause. High-risk individuals from such families continue to be under-identified, despite growing data showing the benefit of pancreas surveillance in this population. We will discuss the current state of clinical surveillance for pancreatic cancer in high-risk individuals, and the role of large-scale collaborative research to accelerate progress toward meaningful improvement in survival.

  Level of Instruction: Basic

  

  Only the live session qualifies for CEUs but when possible, we host the recordings on our website and NSGC recommends participants to use their personal email instead of work email addresses to ensure they receive their CEU certificates.

  

  Ambry Genetics is approved as a provider for continuing education program by NSGC and ASCLS P.A.C.E ® Program.

Jessica Everett, MS, CGC | Presenter

Clinical Assistant Professor of Internal Medicine & Genetic Counselor at the Pancreatic Cancer Center, NYU Langone Health Perlmutter Cancer Center

Jessica Everett is a Clinical Assistant Professor of Internal Medicine and a genetic counselor in the Pancreatic Cancer Center at NYU Langone Health Perlmutter Cancer Center. She has over 20 years of clinical and research experience in cancer genetics, and joined NYU Langone in 2017, where she is entirely focused on pancreatic cancer and pancreatitis. Jessica has served NSGC as co-chair of the Familial Cancer Special Interest Group, member of the Public Policy Committee, and liaison to the American College of Surgeons Commission on Cancer. She currently serves on the Executive Committee of the Pancreatic Cancer Early Detection (PRECEDE) Consortium. She completed her M.S. in Medical Genetics at the University of Cincinnati.

Sarah Campian, MS, CGC | Moderator

Genomic Science Liaison, Ambry Genetics

Sarah Campian joined Ambry Genetics in 2018 after working for four years as a clinical cancer genetic counselor at the Grosfeld Cancer Genetics Center at Beaumont Health in Royal Oak, Michigan. She is a Senior Genomic Science Liaison, working with genetic counselors and other healthcare professionals ordering covering Michigan, Ohio, and Indiana territories. In addition to providing education and clinical support for healthcare providers, she coordinates Case Café, a national educational genetics case conference webinar series and is a lead regional field trainer at Ambry. Sarah received her Bachelors of Science degree in Biology from Saginaw Valley State University. She earned her Masters of Science degree in Genetic Counseling from Wayne State University and is certified by the American Board of Genetic Counseling.